About Livagen
Tetrapeptide bioregulator for hepatocytes; activates gene expression in liver cells; promotes liver cell regeneration; restores lymphocyte activity via liver-mediated immune pathways
Livagen is a synthetic tetrapeptide classified as a Khavinson-class bioregulator targeted at liver and hepatocyte tissue, investigated for cytoprotective and anti-aging effects on hepatocellular gene expression and chromatin organization through proposed regulatory mechanisms analogous to other short Khavinson-class bioregulators. Like other Khavinson bioregulator peptides, livagen is proposed to modulate gene expression in target hepatocyte cells through epigenetic and transcriptional mechanisms, with tissue-specific targeting proposed to support hepatocyte function and liver regenerative capacity under conditions of aging-related cellular stress. Published research on Khavinson-class ultrashort peptides has characterized neuroepigenetic mechanisms of action in aging tissue models and demonstrated peptide regulation of cell differentiation in progenitor populations, providing the class-level mechanistic context for livagen's proposed hepatic regulatory effects. Livagen has no FDA approval or regulatory approval in any major Western jurisdiction; evidence derives entirely from Khavinson-series preclinical and class-level studies with no independent clinical trials published in Western-indexed journals.
Livagen Benefits & Research Areas
Research Signals
Population research notes
These signals reflect research interest areas, not treatment indications.
Regulatory & Evidence
Risk Profile
Generally considered lower risk in research contexts. Risk profile varies by individual — review contraindications before use.
Regulatory Status
- Availability Status
- Research Only
- FDA Status
- Not Evaluated
Russian liver peptide bioregulator (Lys-Glu-Asp-Gly) from Khavinson Institute. Studied for aging and hepatic function. No FDA approval, no NDA or IND. Research chemical in US.
Regulatory status reflects publicly available information and may change. This is not legal or medical advice.
Research Sources
2 sources cited · 2 moderate
2 Reviews
Bioavailability and Biological Activities of Food-Derived Di- and Tripeptides: In Silico and In Vitro Studies
International Journal of Molecular Sciences · 2022
This review examines the biological activities and transport mechanisms of ultrashort di- and tripeptides including livagen, documenting evidence for their immunomodulatory activity in lymphoid and hematopoietic tissues and transport via intestinal peptide transporters relevant to systemic bioavailability.
Short Peptides in the Treatment of Age-Related Diseases
Stem Cell Reviews and Reports · 2020
This review summarizes the geroprotective properties of short regulatory peptides including livagen, documenting their effects on hematopoietic and lymphoid tissue function and longevity in animal models, with discussion of clinical data showing reduced age-related pathology in human cohorts from the Khavinson research program.
Livagen Side Effects & Safety Considerations
Generally considered lower risk in research contexts. Individual response varies — review all considerations before use.
Reported contraindications & considerations
Consult a qualified healthcare professional before making any health decisions. This information is educational only and does not constitute medical advice.
Where to Buy Livagen — Providers & Availability
2 providersClinics
1 providerStay updated on verified Livagen providers
New verified providers added weekly — delivered to your inbox.
Questions to Ask Your Provider
Frequently Asked Questions — Livagen
Livagen is a synthetic tetrapeptide classified as a Khavinson-class bioregulator targeted at liver and hepatocyte tissue, investigated for cytoprotective and anti-aging effects on hepatocellular gene expression and chromatin organization through proposed regulatory mechanisms analogous to other short Khavinson-class bioregulators. Like other Khavinson bioregulator peptides, livagen is proposed to modulate gene expression in target hepatocyte cells through epigenetic and transcriptional mechanisms, with tissue-specific targeting proposed to support hepatocyte function and liver regenerative capacity under conditions of aging-related cellular stress.
liver cell regeneration, hepatoprotection, immune restoration via liver, chromatin activation.
Research on Livagen primarily documents effects related to liver cell regeneration and hepatoprotection and immune restoration via liver and chromatin activation. These are areas covered in preclinical and clinical literature — individual response varies and effects depend on context of use.
Reported contraindications and considerations for Livagen include none established. This is educational information only — consult a qualified healthcare professional before use.
2 providers in the directory currently offer Livagen.
This review examines the biological activities and transport mechanisms of ultrashort di- and tripeptides including livagen, documenting evidence for their immunomodulatory activity in lymphoid and hematopoietic tissues and transport via intestinal peptide transporters relevant to systemic bioavailability.